Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Cash & Equivalents (2019 - 2025)

Legend Biotech filings provide 7 years of Cash & Equivalents readings, the most recent being $286.7 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 77.56% to $286.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $286.7 million, a 77.56% decrease, with the full-year FY2025 number at $286.7 million, down 77.56% from a year prior.
  • Cash & Equivalents hit $286.7 million in Q4 2025 for Legend Biotech, up from $278.9 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $1.3 billion in Q4 2023 to a low of $201.3 million in Q2 2024.
  • Median Cash & Equivalents over the past 5 years was $559.7 million (2023), compared with a mean of $648.4 million.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 446.63% in 2021 and later crashed 83.68% in 2024.
  • Legend Biotech's Cash & Equivalents stood at $688.9 million in 2021, then grew by 14.09% to $786.0 million in 2022, then soared by 62.55% to $1.3 billion in 2023, then decreased by 0.0% to $1.3 billion in 2024, then plummeted by 77.56% to $286.7 million in 2025.
  • The last three reported values for Cash & Equivalents were $286.7 million (Q4 2025), $278.9 million (Q3 2025), and $266.6 million (Q2 2025) per Business Quant data.